Cor Vasa 2009, 51(6):389-391

Význam C-reaktivního proteinu v prevenci kardiovaskulárních nemocí

Hana Rosolová
Centrum preventivní kardiologie II. interní kliniky, Univerzita Karlova Praha - Lékařská fakulta a Fakultní nemocnice v Plzni, Plzeň, Česká republika

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosolová H. Význam C-reaktivního proteinu v prevenci kardiovaskulárních nemocí. Cor Vasa. 2009;51(6):389-391.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tillett WS, Francis T. Serological reaction in pneumonia with a non-protein somatic factor of pneumococcus. J Exp Med 1930;52:561-71. Go to original source... Go to PubMed...
    2. Vlaicu R, Rus HG, Nicolescu F, et al. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 1985;55:35-50. Go to original source...
    3. Mendall MA, Patel P, Ballam L, et al. C-reactive protein and its relation to cardiovascular risk factors: a population based cross-sectional study. Br Med J 1996;312:1061-5. Go to original source... Go to PubMed...
    4. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47. Go to original source...
    5. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburk Cohort Study 1984-1992. Circulation 1999;99:237-42. Go to original source...
    6. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101: 252-25. Go to original source...
    7. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. Go to original source... Go to PubMed...
    8. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protien and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. Go to original source... Go to PubMed...
    9. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6. Go to original source...
    10. Bogaty P, Boyer L, Simard S, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and one month later to predict outcome in patients with acute coronary syndrome. J Am Coll Cardiol 2008;51:2339-46. Go to original source... Go to PubMed...
    11. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem 2008;52:1800-7. Go to original source...
    12. Lim SY, Jeong MH, Bae EH, et al. Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary PCI. Circ J 2005;69:154-8. Go to original source...
    13. Akkus MN, Polat G, Yurtdas M, et al. Admission level of C-reactive protein and plasminogen activator inhibitor 1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J 2009;50:33-45. Go to original source... Go to PubMed...
    14. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44. Go to original source...
    15. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression on coronary atherosclerosis: a randomized controlled trial REVERSAL. JAMA 2004;291:1071-80. Go to original source... Go to PubMed...
    16. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER Study). N Engl J Med 2008;359:2195-207. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes